Metabolic Dysfunction-Associated Steatotic Liver Disease Clinical Trials

17 recruiting

Metabolic Dysfunction-Associated Steatotic Liver Disease Trials at a Glance

33 actively recruiting trials for metabolic dysfunction-associated steatotic liver disease are listed on ClinicalTrialsFinder across 6 cities in 43 countries. The largest study group is Not Applicable with 10 trials, with the heaviest enrollment activity in Taipei, Seattle, and Chandler. Lead sponsors running metabolic dysfunction-associated steatotic liver disease studies include University of California, San Francisco, Aristotle University Of Thessaloniki, and AB Biotics, SA.

Browse metabolic dysfunction-associated steatotic liver disease trials by phase

Treatments under study

About Metabolic Dysfunction-Associated Steatotic Liver Disease Clinical Trials

Looking for clinical trials for Metabolic Dysfunction-Associated Steatotic Liver Disease? There are currently 17 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metabolic Dysfunction-Associated Steatotic Liver Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metabolic Dysfunction-Associated Steatotic Liver Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 33 trials

Recruiting
Phase 2

Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial

MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseFatty Liver Disease, NonalcoholicOverweight (BMI > 25)
AB Biotics, SA60 enrolled1 locationNCT07193927
Recruiting
Phase 1Phase 2

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis
Regeneron Pharmaceuticals132 enrolled3 locationsNCT06836609
Recruiting
Phase 3

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company4,500 enrolled561 locationsNCT07165028
Recruiting
Phase 1

Developing Microbial Therapy for MASLD: From Mechanism to Clinical Validation

Metabolic Dysfunction-Associated Steatotic Liver Disease
Leeuwenhoek Laboratories Co. Ltd.40 enrolled1 locationNCT07488975
Recruiting
Not Applicable

A Large Language Model-based Chatbot for Alcohol Reduction in Patients With Metabolic Alcohol-Related Liver Disease

Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Alcohol-Related Liver Disease
The University of Hong Kong50 enrolled1 locationNCT07450144
Recruiting

Expanded Studies on the SCAPIS Stockholm Reexamination Cohort

Heart FailureCoronary Artery DiseaseOral Microbiota+9 more
Danderyd Hospital1,400 enrolled1 locationNCT07476703
Recruiting

The Establishment of Hong Kong Diabetes Steatotic Liver Disease Register

Metabolic Dysfunction-Associated Steatotic Liver DiseaseType 2 Diabetes (T2DM)
Chinese University of Hong Kong1,000 enrolled1 locationNCT07437157
Recruiting

Spleen Stiffness Measurement for the Detection of Advanced Fibrosis

MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Fondazione Policlinico Universitario Agostino Gemelli IRCCS500 enrolled1 locationNCT07440511
Recruiting
Phase 3

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc.1,350 enrolled331 locationsNCT06318169
Recruiting
Phase 4

Effect of a GnRH Analog on Hepatic Steatosis

EndometriosisMetabolic Dysfunction-Associated Steatotic Liver DiseaseNonalcoholic Fatty Liver
Aristotle University Of Thessaloniki62 enrolled2 locationsNCT06523530
Recruiting
Early Phase 1

Efficacy and Safety of Rifaximin-α in Treating MASLD

Metabolic Dysfunction-Associated Steatotic Liver Disease
Shanghai Changzheng Hospital60 enrolled1 locationNCT07381257
Recruiting

Quantitative Ultrasound to Assess Steatotic Liver Disease in Children

MASLDMASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
University of California, San Diego120 enrolled1 locationNCT06706856
Recruiting

Study of the Link Between MASH ( Metabolic Dysfunction-Associated Steatohepatitis) and MAMs (Mitochondria-Associated Membranes ) Alteration in Patients Undergoing Bariatric Surgery - MAMBA

Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Dysfunction-Associated SteatohepatitisSleeve Gastrectomy+1 more
Hospices Civils de Lyon20 enrolled2 locationsNCT06868992
Recruiting

Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)

MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Centre Hospitalier Universitaire de la Guadeloupe600 enrolled3 locationsNCT07330830
Recruiting

Thermoacoustic Method for Estimating Liver Fat Fraction

MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)Fatty Liver Disease, Nonalcoholic
Endra Lifesciences49 enrolled1 locationNCT07321925
Recruiting
Not Applicable

Effect of Indianized Version of Mediterranean Diet vs. Low Fat Diet on Hepatic Steatosis in Overweight Children and Adolescent With MASLD

Metabolic Dysfunction-Associated Steatotic Liver Disease
Institute of Liver and Biliary Sciences, India134 enrolled1 locationNCT06768216
Recruiting
Not Applicable

Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis

MASLDMetabolic Dysfunction-Associated Steatotic Liver Disease
University of Alabama at Birmingham28 enrolled1 locationNCT06735924
Recruiting
Not Applicable

Corazones Unidos Study

CVD - Cardiovascular DiseaseMASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
University of Arizona45 enrolled1 locationNCT07298213
Recruiting

The Development of MASLD Among Survivors of Breast or Colorectal Cancer

Breast Cancer SurvivorsColorectal (Colon or Rectal) Cancer SurvivorsMASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
University of Bern200 enrolled1 locationNCT07280143
Recruiting
Not Applicable

Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis

NAFLD - Non-Alcoholic Fatty Liver DiseaseMASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
ContextVision AB110 enrolled1 locationNCT07270601